1. A hanger running tool, comprising:
a radially outer surface having at least one recess extending circumferentially about at least a portion of a periphery of the hanger running tool; and
at least one alignment element disposed within the at least recess, wherein the at least one alignment element protrudes radially outward from the radially outer surface and is configured to contact a radially inner surface of a wellhead as the hanger running tool moves within the wellhead.
2. The hanger running tool of claim 1, wherein the at least one recess comprises a plurality of recesses each extending circumferentially about a respective portion of the periphery of the hanger running tool, and the recesses of the plurality of recesses are circumferentially separated from one another to enable fluid to flow through at least one axial flow slot of the hanger running tool.
3. The hanger running tool of claim 2, wherein the at least one alignment element comprises a plurality of alignment elements, and each of the plurality of alignment elements is disposed in a respective one of the plurality of recesses.
4. The hanger running tool of claim 1, wherein the at least one recess comprises a plurality of recesses each extending circumferentially about a respective portion of the periphery of the hanger running tool, and the recesses of the plurality of recesses are separated from one another along an axial axis of the hanger running tool.
5. The hanger running tool of claim 1, wherein the at least one recess comprises an upper axial surface and a lower axial surface that converge toward one another along a direction extending from an interior portion of the hanger running tool to the radially outer surface.
6. The hanger running tool of claim 1, wherein the at least one alignment element comprises a curved radially outer wall.
7. The hanger running tool of claim 1, wherein the at least one alignment element is formed from a polymer material, an elastomer material, a fabric material, or any combination thereof.
8. The hanger running tool of claim 1, wherein the at least one alignment element is coupled to the at least one recess via an adhesive.
9. A hanger running tool, comprising:
a radially outer surface;
a plurality of axial flow slots formed in the radially outer surface to facilitate flow of fluid along the hanger running tool; and
at least one alignment element disposed circumferentially about a periphery of the hanger running tool between adjacent axial flow slots of the plurality of axial flow slots, wherein the alignment element protrudes radially outward from the radially outer surface to facilitate alignment of the hanger running tool within a bore of a wellhead.
10. The hanger running tool of claim 9, comprising at least one recess extending circumferentially about the periphery of the hanger running tool between adjacent axial flow slots of the plurality of axial flow slots, wherein the at least alignment element is disposed within the at least one recess.
11. The hanger running tool of claim 10, wherein the at least one recess comprises an upper axial surface and a lower axial surface that converge toward one another along a direction extending from an interior portion of the hanger running tool to the radially outer surface.
12. The hanger running tool of claim 9, wherein the at least one alignment element comprises a plurality of alignment elements each extending circumferentially between a respective pair of adjacent axial flow slots of the plurality of axial flow slots, wherein the alignment elements of the plurality of alignment elements are separated from one another along an axial axis of the hanger running tool.
13. The hanger running tool of claim 9, wherein the at least one alignment element comprises a curved radially outer wall.
14. The hanger running tool of claim 9, wherein the at least one alignment element is formed from a polymer material, an elastomer material, a fabric material, or any combination thereof.
15. A hanger running tool, comprising:
a plurality of alignment elements each protruding from a radially outer surface of the hanger running tool, wherein each of the plurality of alignment elements extends circumferentially about at least a portion of a periphery of the hanger running tool and is configured to block contact between the radially outer surface of the hanger running tool and a radially inner surface of a wellhead in a region proximate to the alignment element as the hanger running tool moves or turns within the wellhead.
16. The hanger running tool of claim 15, wherein each of the plurality of alignment elements is disposed within a respective recess formed in the radially outer surface of the hanger running tool.
17. The hanger running tool of claim 16, wherein at least one respective recess comprises an upper axial surface and a lower axial surface that converge toward one another along a direction extending from an interior portion of the hanger running tool to the radially outer surface.
18. The hanger running tool of claim 15, wherein the plurality of alignment elements are circumferentially disposed between axial flow slots of the hanger running tool to enable a flow of fluid through the axial flow slots.
19. The hanger running tool of claim 15, wherein at least one of the plurality of alignment elements comprises a curved radially outer wall.
20. The hanger running tool of claim 15, wherein at least one of the plurality of alignment elements is formed from a polymer material, an elastomer material, a fabric material, or any combination thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula (I)
5
wherein:
R1 is hydrogen; C6-14aryl; or heteroaryl, optionally substituted with one or more substituents selected from the group consisting of C1-6alkoxy, nitro, halogen, amino, hydroxy, carboxylate and esters thereof, carboxyalkyl, CONHR6, and CONR6R7, wherein R6 and R7, which may be the same or different, are independently selected from C1-8alkyl, C1-8alkylaryl or C6-14aryl;
R2 and R3 are independently selected from hydrogen or C1-8alkyl, C3-8cycloalkyl, C2-8alkenyl, C5-8cycloalkenyl, C6-14aryl, or aralkyl wherein each C1-8alkyl, C3-8cycloalkyl, C2-8alkenyl, C5-8cycloalkenyl, C6-14aryl or aralkyl may be optionally substituted with one or more substituents selected from the group consisting of C1-8alkyl, halo, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, SH, thioalkyl, carboxylate and esters thereof, carboxyalkyl, CONHR6, and CONR6R7, wherein R6 and R7, which may be the same or different, are independently selected from C1-8alkyl, C1-8alkylaryl or C6-14aryl; or R2 and R3 can together form a 3- to 8-membered ring;
R4 is OR8, NR8R9 or SR8, where R8 and R9, which may be the same or different, are independently selected from hydrogen, or C1-8alkyl, C3-8cycloalkyl, C2-8alkenyl, C5-8cycloalkenyl, or aralkyl, wherein each C1-8alkyl, C3-8cycloalkyl, C2-8alkenyl, C5-8cycloalkenyl, or aralkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, SH, thioalkyl, carboxylate and esters thereof, carboxyalkyl, CONHR6, and CONR6R7, wherein R6 and R7, which may be the same or different, are independently selected from C1-8alkyl, C1-8alkylaryl or C6-14aryl;
R5 is hydrogen; C1-8alkyl; or C6-14aryl; or R2 and R5 may together form a 5- or 6-membered ring; or R3 and R5 may together form a 5- or 6-membered ring;
X is C1-6alkoxy, optionally substituted by C3-6cycloaklyl; C3-8cycloalkyloxy; aryloxy, aralkyl or aralkyloxy in which the aryl may optionally be substituted with C1-8alkyl, hydroxy, or halogen; C3-6cycloalkylthio; C1-8alkylthio; arylthio, or aralkylthio in which the aryl may optionally be substituted with C1-8alkyl, hydroxy, or halogen; or X is a heterocyclic group containing an oxygen atom or one or two nitrogen atoms, and 3-7 carbon atoms with optional double bonds in the ring, optionally containing a sulfur andor oxygen heteroatom and optionally substituted on the ring by one or more C1-8alkyl, hydroxy or halogen groups, C3-6cycloalkylthio, aralkylthio in which the aryl may be substituted with C1-8alkyl, hydroxy or halogen; or X represents an imidazolylthio group in which the imidazolyl moiety may be substituted with C1-8alkyl andor C substituted with nitro; or X represents an amino group which is mono- or di-substituted by C1-8alkyl, C1-6alkoxy, hydroxyC1-8alkyl andor C3-6cycloalkyl, C6-14aryl, aralkyl, in which the C6-14aryl may be optionally substituted with C1-8alkyl, hydroxy, halogen or allyl optionally substituted with mono- or di-alkyl or alkoxy groups;
or a pharmaceutically acceptable derivative thereof; provided that X cannot be amino monosubstituted with cyclopropyl.
2. A compound of formula (I) according to claim 1 wherein R1 is C6-14aryl; R2 and R3 are independently selected from hydrogen, C1-8alkyl, aralkyl or C6-14aryl optionally substituted with C1-8alkyl; R4 is OR8, where R8 is selected from C1-8alkyl or aralkyl; R5 is hydrogen; and X represents C1-6alkoxy or C1-6alkylthio; or X represents a heterocyclic group containing a nitrogen atom, and 3-7 carbon atoms; or X represents an amino group which is mono- or di-substituted by C1-6alkyl, C1-6alkoxy, hydroxyC1-6alkyl andor C3-6cycloalkyl, C6-14aryl, aralkyl, in which the aryl may be optionally substituted with C1-8alkyl, hydroxy, halogen or allyl optionally substituted with mono- or di-alkyl or alkoxy groups; or a pharmaceuticallly acceptable derivative thereof provided that X cannot be amino monosubstituted with cyclopropyl.
3. A compound selected from the group consisting of
(1S,cis)-4-2-Amino-6-(1-azetidinyl)-9H-purin-9-yl-2-cyclopentene-1-methanol O-phenyl(methoxy-L-alaninyl)phosphoramidate;
(1S,cis)-4-2-Amino-6-(cyclopropylmethylamino)-9H-purin-9-yl-2-cyclopentene-1-methanol O-phenyl(methoxy-L-alaninyl)phosphoramidate;
(1S,cis)-4-(2-Amino-6-butoxy-9H-purin-9-yl)-2-cyclopentene-1-methanol O-phenyl(methoxy-L-alaninyl)phosphoramidate;
(1S,cis)-4-(2-Amino-6-methoxy-9H-purin-9-yl)-2-cyclopentene-1-methanol O-phenyl(methoxy-L-alaninyl)phosphoramidate;
(1S,cis)-4-(2-Amino-6-(propylamino)-9H-purin-9-yl-2-cyclopentene-1-methanol O-phenyl(methoxy-L-alaninyl)phosphoramidate;
(1S,cis)-4-2-Amino-6-(isopropylamino)-9H-purin-9-yl-2-cyclopentene-1-methanol O-phenyl(methoxy-L-alaninyl)phosphoramidate;
(1S,cis)-4-2-Amino-6-(allylthio)-9H-purin-9-yl-2-cyclopentene-1-methanol O-phenyl(methoxy-L-alaninyl)phosphoramidate;
(1S,cis)-4-(2,6-Diamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-phenyl(methoxy-L-alaninyl)phosphoramidate;
(1S,cis)-4-2-Amino-6-(cyclopropylmethylamino)-9H-purin-9-yl-2-cyclopentene-1-methanol O-phenyl(methoxy-,-dimethylglycinyl)phosphoramidate;
(1S,cis)-4-2-Amino-6-(cyclopropyl methylamino)-9H-purin-9-yl-2-cyclopentene-1-methanol O-phenyl(benzyloxy-L-alaninyl)phosphoramidate;
(1S,cis)-4-2-Amino-6-(cyclopropyl methylamino)-9H-purin-9-yl-2-cyclopentene-1-methanol O-phenyl(methoxy-L-phenylalaninyl)phosphoramidate;
and pharmaceutically acceptable derivatives thereof.
4. A compound according to any of claims 1 to 3 in the form of a single isomer.
5. A compound according to any of claims 1 to 3 in the form of a mixture of diastereomers.
6. A method of treating a virus infection in a human comprising administering to said human an effective anti-virus treatment amount of a compound of formula (I) according to any of claims 1 to 3 or a pharmaceutically acceptable derivative thereof.
7. The method according to claim 6 wherein the virus is selected from Human Immunodeficiency Virus, hepatitis B virus, and hepatitis C virus.
8. A method of treating a hepatitis B virus infection in a human comprising administering to said human an effective anti-hepatitis B treatment amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable derivative thereof.
9. A method of treating a HIV infection in a human comprising administering to said human an effective anti-HIV treatment amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable derivative thereof.
10. A compound according to any of claims 1 to 3 wherein the pharmaceutically acceptable derivative is a salt.
11. A pharmaceutical compostition comprising an effective anti-viral amount of a compound of formula (I) according to any of claims 1 to 3 or a pharmaceutically acceptable derivative thereof together with a pharmaceutically acceptable carrier therefor.
12. The pharmaceutical composition according to claim 11, further comprising an antiviral agent other than a compound of formula (I).
13. A pharmaceutical composition according to claim 11 or 12 in the form of a tablet or capsule.
14. A pharmaceutical composition according to claim 11 or 12 in the form of a solution, suspension or syrup.
15. A compound of formula (I) as claimed in claim 1 for use in medical therapy.
16. Use of a compound of formula (I) as claimed in claim 1 in the manufacture of a medicament for the treatment or prophylaxis of a virus infection.